Not satisfied with simply changing personnel, Japanese drugmaker Astellas has announced a new management structure, effective ...

Japanese drugmaker Astellas Pharma says it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labor ...

The new Astellas agreement comes a few months after the FORTIS study of AT845 was placed under a clinical hold by the FDA after a serious adverse event – peripheral sensory neuropathy – was ...

Astellas is ready to launch its first digital ... Ultimately, the aim is to prevent acute decompensation events and re-hospitalisations. Digitiva (formerly known as Z1608) has been listed by ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

Many factors could cause actual future events to differ materially from the ... ginkgo-bioworks-partners-with-universal-cells-an-astellas-company-to-advance-next-generation-ipsc-derived-cell ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue ...

The Illinois Biotechnology Innovation Organization (iBIO), the premier trade association representing the state's vibrant life sciences sector with 94,000 jobs, today announced the appointment ...

GC Labs, a leading clinical laboratory in South Korea, announced the successful completion of the second day of the Medlab Middle East 2025, which is being held at the Dubai World Trade Centre (DWTC), ...